Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 20/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217592 | 0.89 | AKR1B1 (0.50) | AKR1B1 | |
| SCHEMBL15217599 | 0.89 | AKR1B1 (0.50) | AKR1B1 | |
| SCHEMBL362133 | 0.88 | AKR1B1 (0.54) | AKR1B1 | |
| SCHEMBL361207 | 0.88 | AKR1B1 (0.54) | AKR1B1 | |
| SCHEMBL360713 | 0.86 | AKR1B1 (0.64) | AKR1B1 | |
| SCHEMBL15217611 | 0.86 | AKR1B1 (0.55) | AKR1B1 | |
| SCHEMBL15217607 | 0.86 | AKR1B1 (0.55) | AKR1B1 | |
| SCHEMBL19142553 | 0.85 | AKR1B1 (0.52) | AKR1B1 | |
| SCHEMBL361113 | 0.85 | AKR1B1 (0.72) | AKR1B1 | |
| SCHEMBL15217621 | 0.85 | AKR1B1 (0.54) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2024-06-06 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-22 | — | — | US | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| EP-4124620-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2023-02-01 | — | — | EP | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3597650-B1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | UNIV COLUMBIA (US) | 2022-09-07 | — | — | EP | disclosed |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2020-09-17 | — | — | US | disclosed |
| EP-2945934-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-03-12 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| US-8916563-B2 | Aldose reductase inhibitors and uses thereof | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-12-23 | — | — | US | disclosed |
| WO-2014113380-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2014-07-24 | — | — | WO | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-08-29 | — | — | US | disclosed |
| EP-2593456-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | The Trustees of Columbia University in the City of New York (US) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012009553-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180907-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-20200289512-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-11529349-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-20150072989-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-20130225592-A1 | ALDOSE REDUCTASE INHIBITORS AND USES THEREOF | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
| US-11730737-B2 | Aldose reductase inhibitors and uses thereof | ALDOA, AKR1B1, AKR1C2 | AKR1B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.